Onco Wiki / Biomarcador

O SMO ativa a mutação (Luxado)

Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.

IDBIO-SMO
TipoBiomarcador
Alegais
SMO mutationАктивуюча мутація SMO (Smoothened)
Estadoreviewed 2026-05-04 | pending_clinical_signoff
DoençasDIS-BCC
FontesSRC-ESMO-SARCOMA-2024 SRC-NCCN-SKIN-2025

Fatos de biomarcadores

Tipo de biomarcadorgene_mutation
Detalhes da mutação{"exon": "multiple", "functional_impact":"activando", "gene": SMO, "variant_type":", "missense activando"}
Medição
MétodoPanel NGS tumoral (com base em ADN); variantes comuns: W535L, L412F, Q477E, S533N
Procura de ação{"gene": "SMO", "variant": "activating_mutation"}
Biomarcadores relacionadosBIO-PTCH1

Notas

SMO (Smoothened) is a G-protein-coupled receptor that transmits Hedgehog (HH) signaling. Normally suppressed by PTCH1; activated when PTCH1 loses its inhibitory function (whether via PTCH1 loss-of-function or SMO gain-of-function mutation). SMO activating mutations (~10–20% of BCCs) and PTCH1 loss-of-function (~90% of BCCs) both result in constitutive HH pathway activation. Vismodegib and sonidegib are SMO antagonists — they bind the SMO transmembrane domain and block downstream HH signaling (GLI1/2 repression). In practice, BCC HHI therapy does not require pre-testing for SMO vs PTCH1 mutation — all BCCs have HH pathway activation. SMO mutations also occur in sporadic medulloblastoma (SHH subtype) and rarely in other tumors. Resistance: secondary SMO mutations (D473H most common) emerge during vismodegib therapy, driving acquired resistance. Sonidegib may be active in some vismodegib-resistant D473H mutants.

Usado por

Relevância terapêutica

Biomarcador

Doença

Indicação